Shenghui Tang

TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.

TL;DR: In patients with imatinib refractory or intolerant GIST, time-to-tumor progression of sunitinib-treated patients was superior to that of placebo- treated patients, and in patients with metastatic renal cell carcinoma, partial responses were observed.

TL;DR: The most common adverse reactions in patients treated with olaparib were anemia, nausea, fatigue, vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngritis/upper respiratory infection, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash, and abdominal pain/discomfort.

TL;DR: Sorafenib received FDA regular approval for the treatment of advanced RCC based on the persuasive magnitude of improvement in PFS with acceptable safety, and the recommended dose is 400 mg twice daily taken either 1 h before or 2 h after meals.

TL;DR: The FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clinical benefit in the ongoing and fully accrued confirmatory trial PALOMa-2 are summarized.